– May 1, 2003
May 1, 2003
View Issues
-
Chemotherapy Offers Survival Benefit in Androgen-Independent Prostate Cancer
In a trial that included androgen-independent prostate cancer patients, 2 drug regimens were shown by randomized phase II analysis to be comparable. Both produced survival advantage when compared to prior series, including those in which mitoxantrone and prednisone were used. -
Prognostic Factors for Patients with Advanced-Stage Serous Borderline Tumors of the Ovary
In this series, the only prognostic factor for patients with advanced-stage borderline tumor is the type of peritoneal implant. More patients died of the treatments complications than of the disease itself. -
Radiotherapy Alone for Primary Cutaneous B-cell Lymphoma
There are no well-defined guidelines for the treatment of primary cutaneous B-cell lymphoma (PCBCL). Since it is an uncommon diagnosis, it is unlikely that answers will come from randomized trials. This retrospective study from 2 German centers evaluated outcomes from a cohort of 35 patients and concluded that radiotherapy to all visible lesions is the treatment of choice. -
A Phase II Study of Docetaxel in Paclitaxel-Resistant Ovarian and Peritoneal Carcinoma
Docetaxel is active in paclitaxel-resistant ovarian and peritoneal cancer, but, in view of significant hematologic toxicity, further study is warranted to ascertain its optimal dose and schedule. -
Women’s Perceptions About Treatment Decision-Making for Ovarian Cancer
Women with advanced epithelial ovarian cancer did not describe the treatment decision-making process as shared; rather, they described an interaction that was directed by their physician. -
Reducing Mortality in Sickle Cell Disease with Hydroxyurea
Participants in the initial Multicenter Study of Hydroxyurea in Sickle Cell Anemia interventional trial were followed, upon completion of that trial for up to 9 years, to determine the long-term effects of treatment. In this publication of the observational phase of the MSH trial, there is noted a 40% reduction in mortality for those who had received a year or more of the drug. -
Clinical Briefs in Primary Care Supplement